Keyword: Bristol-Myers Squibb
BMS forms new I-O deal with Ono, Eisai's Lenvima wins NICE nod in kidney cancer, Sanofi tries to dig out of Philippines Dengvaxia fallout.
Bristol-Myers has entered the FDA fast lane with its Opdivo-plus-Yervoy combo, driving toward a new use in certain kidney cancer patients.
Investors in five Big Pharmas want the companies to review whether their compensation plans effectively reward executives who hike prices.
Pharma TV ad spending has already officially topped last year with a total of $3.2 billion through the end of November, according to iSpot.tv data.
With Tecentriq and Avastin's trial win over Sutent in first-line kidney cancer, Roche scored new points in its quest to advance the combo.
It feels as though we say this every year, but it bears repeating: From CEOs and COOs to division chiefs and venture capital partners, women are taking the lead and making an impact all over the life sciences industry.
Bristol-Myers Squibb Friday touted strong Opdivo results for lung cancer in previously treated Chinese patients.
As Merck stacks up indications for its cancer fighter Keytruda, it’s also adding treatment areas to its cancer awareness umbrella campaign.
Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.